Head and neck cancer
Not yet recruitingStudy on the Effects of Tepotinib and Cetuximab for Patients with Platinum-Resistant Head and Neck Cancer After Immunotherapy Relapse
Study on the Effects of Tepotinib and Cetuximab for Patients with Platinum-Resistant Head and Neck Cancer After Immunotherapy Relapse
- Disease:Head and neck cancer
- Substances:CetuximabTepotinib
Italy- Participants:18–64 years · 65+ years
- Substances:Cetuximab
- Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia






